J. Lormeau

发表

Antithrombin III: structural and functional aspects.

M. Delarue, D. Moras, L. Mourey, 1990, Biochimie.

Synthesis of thrombin-inhibiting heparin mimetics without side effects

J. Herbert, M. Petitou, J. Lormeau, 1999, Nature.

The Mode of Action of CY216 and CY222 in Plasma

H. Hemker, S. Béguin, J. Lormeau, 1992, Thrombosis and Haemostasis.

Synthesisof thrombin-inhibitingheparinmimetics without sideeffects

J. Herbert, M. Petitou, J. Lormeau, 2022 .

Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group

M. Karnovsky, J. Castellot, M. Petitou, 1986, The Journal of cell biology.

Heparin‐derived oligosaccharides: Affinity for acidic fibroblast growth factor and effect on its growth‐promoting activity for human endothelial cells

M. Petitou, J. Choay, J. Lormeau, 1989, Journal of cellular physiology.

Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect.

E. De Clercq, R. Pauwels, M. Baba, 1993, Journal of medicinal chemistry.

ANTITHROMBOTIC ACTIVITY OF A SYNTHETIC HEPARIN PENTASACCHARIDE IN A RABBIT STASIS THROMBOSIS MODEL USING DIFFERENT THROMBOGENIC CHALLENGES

M. Samama, J. Fareed, M. Petitou, 1987, Thrombosis and Haemostasis.

Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model.

M. Samama, J. Fareed, M. Petitou, 1986, Thrombosis research.

STRUCTURAL STUDIES ON A BIOLOGICALLY ACTIVE HEXASACCHARIDE OBTAINED FROM HEPARIN

J. Fareed, M. Petitou, J. Choay, 1981, Annals of the New York Academy of Sciences.

Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties.

B. Boneu, M. Petitou, J. Choay, 1988, Thrombosis research.

SR 90107A/Org 31540, a Novel Anti‐Factor Xa Antithrombotic Agent

J. Herbert, P. Zandberg, J. Necciari, 1997 .

New synthetic heparin mimetics able to inhibit thrombin and factor Xa.

J. Herbert, J. Hérault, M. Petitou, 1999, Bioorganic & medicinal chemistry letters.

The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies.

G. Torri, M. Petitou, J. Choay, 1981, The Biochemical journal.

Synthesis and biological activity of a new anti-factor Xa pentasaccharide with a C-interglycosidic bond

J. Herbert, J. Mallet, M. Petitou, 1997 .

Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.

J. Herbert, B. Tardy, J. Amiral, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.

J. Herbert, J. Hérault, J. Lormeau, 1996, The Journal of pharmacology and experimental therapeutics.

[Low molecular weight oligosaccharides active in plasma against factor Xa. II. New structural elements and antithrombotic activity (author's transl)].

J. Fareed, M. Petitou, J. Choay, 1981, Annales pharmaceutiques francaises.

The first total synthesis of the antithrombin III binding site of porcine mucosa heparin

P. Lei, M. Petitou, J. Choay, 1991 .

[Low molecular weight oligosaccharides active in plasma against factor Xa (author's transl)].

M. Petitou, J. Choay, J. Lormeau, 1981, Annales pharmaceutiques francaises.

Interaction of heparin and antithrombin III. The role of O-sulfate groups.

M. Petitou, J. Choay, J. Lormeau, 1988, European journal of biochemistry.

Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III.

D. Atha, R. Rosenberg, M. Petitou, 1987, Biochemistry.

Anti-Xa active heparin oligosaccharides.

G. Torri, M. Petitou, J. Choay, 1980, Thrombosis research.

Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge.

M. Karnovsky, J. Castellot, M. Petitou, 1989, The Journal of biological chemistry.

First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin.

J. Herbert, C. V. van Boeckel, M. Petitou, 1998, Angewandte Chemie.

Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.

J. Herbert, J. Hérault, P. Hoffmann, 1998, Blood.

O-acylated heparin derivatives with low anticoagulant activity decrease proliferation and increase alpha-smooth muscle actin expression in cultured arterial smooth muscle cells.

A. Desmoulière, G. Gabbiani, J. Herbert, 1992, European journal of pharmacology.

Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo.

M. Karnovsky, M. Petitou, J. Choay, 1991, The American journal of pathology.

Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin.

J. Herbert, J. Hérault, J. Lormeau, 1996, Thrombosis and haemostasis.

Glycosaminoglycans enhance megakaryocytopoiesis by modifying the activities of hematopoietic growth regulators

J. Maffrand, M. Pascal, M. Petitou, 1996, Journal of cellular physiology.

Fraxiparin, a low‐molecular‐weight heparin, stimulates megakaryocytopoiesis in vitro and in vivo in mice

J. Maffrand, M. Pascal, M. Petitou, 1994, British journal of haematology.

Heparin, Heparan Sulfate, Smooth Muscle Cells, and Atherosclerosis a

M. Karnovsky, J. Castellot, M. Petitou, 1989, Annals of the New York Academy of Sciences.

Influence of variations in the chemical structure of heparin on its anticoagulant and anti-factor Xa activities.

J. Lormeau, A. Perlin, L. Ayotte, 1981, Thrombosis research.

Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues.

J. Herbert, J. Hérault, J. Lormeau, 1997, Thrombosis research.

Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.

G. Houin, B. Boneu, C. V. van Boeckel, 1994, Blood.

Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits

G. Houin, B. Boneu, M. Petitou, 1992, British journal of haematology.

Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.

G. Houin, B. Boneu, M. Petitou, 1990, The Journal of laboratory and clinical medicine.

Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).

J. Herbert, J. Hérault, M. Petitou, 1997, Journal of medicinal chemistry.

Comparative Inhibition of Extrinsic and Intrinsic Thrombin Generation by Standard Heparin, a Low Molecular Weight Heparin and the Synthetic ATIII-Binding Pentasaccharide

J. Hérault, J. Lormeau, J. Herault, 1993, Thrombosis and Haemostasis.

Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.

M. Petitou, J. Choay, J. Lormeau, 1983, Biochemical and biophysical research communications.

Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.

J. Herbert, J. Hérault, M. Petitou, 1999, Bioorganic & medicinal chemistry letters.

Introducing a C-interglycosidic bond in a biologically active pentasaccharide hardly affects its biological properties.

J. Herbert, J. Hérault, J. Mallet, 1998, Bioorganic & medicinal chemistry.

Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II.

B. Boneu, M. Petitou, J. Choay, 1988, Biochimica et biophysica acta.

Heparin Reverses the Procoagulant Properties of Stimulated Endothelial Cells

B. Boneu, J. Lormeau, P. Sié, 1996, Thrombosis and Haemostasis.

Is there a unique sequence in heparin for interaction with heparin cofactor II? Structural and biological studies of heparin-derived oligosaccharides.

B. Perly, M. Petitou, J. Choay, 1988, The Journal of biological chemistry.

Pharmacokinetic study of three synthetic AT‐binding pentasaccharides in various animal species‐extrapolation to humans

J. Herbert, J. Hérault, J. Lormeau, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216

G. Houin, B. Boneu, M. Petitou, 1994 .

Selectively O-acylated glycosaminoglycan derivatives

C. Simenel, M. Petitou, J. Choay, 1992 .

Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects.

G. Houin, B. Boneu, M. Petitou, 1992, The Journal of laboratory and clinical medicine.

Pharmacological Properties of a Low Molecular Weight Butyryl Heparin Derivative (C4-CY 216) with Long Lasting Effects

G. Houin, B. Boneu, M. Petitou, 1992, Thrombosis and Haemostasis.

First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin.

J. Herbert, C. V. van Boeckel, M. Petitou, 1998, Angewandte Chemie.

Heparin and Low Molecular Weight Heparins Inhibit Prothrombinase Formation but not its Activity in Plasma

F. Ofosu, S. Craven, J. Lormeau, 1994, Thrombosis and Haemostasis.

Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase.

J. Herbert, J. Hérault, J. Lormeau, 1997, The Journal of pharmacology and experimental therapeutics.

Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs.

M. Petitou, J. Choay, J. Lormeau, 1991, Nature.

Binding of Heparin Fractions to von Willebrand Factor: Effect of Molecular Weight and Affinity for Antithrombin III

P. Legendre, D. Baruch, C. Denis, 1994, Thrombosis and Haemostasis.

Contribution of monosaccharide residues in heparin binding to antithrombin III.

D. Atha, R. Rosenberg, M. Petitou, 1985, Biochemistry.

Molecular profiling and weight determination of heparins and depolymerized heparins.

J. Fareed, D. Hoppensteadt, J. Lormeau, 1995, Journal of pharmaceutical sciences.

Standard Heparin Enhances the Antithrombotic Activity of Dermatan Sulfate in the Rabbit but CY 216 Does Not

B. Boneu, M. Petitou, J. Choay, 1988, Thrombosis and Haemostasis.

Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit.

G. Houin, B. Boneu, M. Petitou, 1992, Thrombosis research.

The Effect of the Synthetic Pentasaccharide SR 90107/ORG 31540 on Thrombin Generation Ex Vivo Is Uniquely due to ATIII-Mediated Neutralization of Factor Xa

J. Hérault, J. Lormeau, J C Lormeau, 1995, Thrombosis and Haemostasis.

Human umbilical vein endothelial cells express high affinity receptors for factor Xa

J. Herbert, F. Bono, J. Lormeau, 1997, Journal of cellular physiology.

Contribution of Erythrocytes to Thrombin Generation in Whole Blood

J. Herbert, J. Hérault, J. Lormeau, 1999, Thrombosis and Haemostasis.

Low affinity heparin is an antithrombotic agent.

D. Lane, J. Lormeau, A. Davies, 1994, Thrombosis and haemostasis.

Pharmacological Properties of CY 216 and of Its ACLM and BCLM Components in the Rabbit

G. Houin, B. Boneu, S. Salvin, 1994, Thrombosis and Haemostasis.

Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.

J. Herbert, J. Hérault, M. Petitou, 1996, Circulation research.

[Duodenal absorption of a low molecular weight heparin in rabbits].

A. Massé, J. Lormeau, C. Doutremépuich, 1984, Pathologie-biologie.

Oral administration of low molecular weight heparin fractions in rabbits.

J. Lormeau, C. Doutremépuich, F. Toulemonde, 1985, Seminars in Thrombosis and Hemostasis.

Long‐term persistence of low‐molecular‐weight material with anti‐factor Xa activity contributes to anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit

J. Herbert, J. Hérault, B. Boneu, 1997, Blood Coagulation and Fibrinolysis.

Quantum leap?

M. Petitou, J. Choay, J. Lormeau, 1991, Nature.

Patents and literature

E. Balazs, R. Wallace, C. Cooney, 1986 .

ANTITHROMBOTIC ACTIVITY OF A SYNTHETIC HEPARIN PENTASACCHARIDE IN A RABBIT STASIS THROMBOSIS MODEL USING DIFFERENT THROMBOGENIC CHALLENGES

J. Lormeau, M. M. Samama, Jeanine M. Walenga, 1987, Thrombosis and Haemostasis.